New Human Trial: 20% More Mitochondria in Immune Cells | Dr Anurag Singh
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →About this video
Creator description · original textText language: English
Dr. Anurag Singh discusses the MitoImmune trial published in Nature Aging showing urolithin A increased CD8 T-cells by 20% and enhanced immune clearance capacity in just 28 days. Learn why immune health may be the key to longevity.
Some links are affiliate links so we will earn a commission when they are used to purchase products.
If you would like to support our channel please consider joining our Patreon https://patreon.com/ModernHealthspan
~~~~~~~~~~~~~~
Time-Line Mitopure Urolithin A, 10% off Code MODERN https://timeline.sjv.io/k4JrNx
~~~~~~~~~~~~~~
The MitoImmune trial, published in Nature Aging, studied 50 middle-aged adults for 28 days. Results showed urolithin A increased stem cell-like CD8 T-cells and boosted mitochondria in immune cells by 20%. Immune cells also showed enhanced clearance capacity against bacteria and viruses.
Dr. Anurag Singh explains why the immune system is one of the first organs affected by aging, how mitochondrial decline impairs vaccine response in older adults, and the emerging field of immunometabolism. He discusses ongoing trials combining urolithin A with cancer immunotherapy checkpoint inhibitors and future studies on vaccination response.
If you're concerned about immune aging, infection susceptibility, or maintaining immune function as you age, this video reveals why mitochondrial health in immune cells may be the foundation of healthy aging.
🔢Chapters
0:00 Introduction to MitoImmune Trial
2:37 Trial Results: 20% More Mitochondria in CD8 T-Cells
4:42 Why Fatty Acid Oxidation Matters for Immune Cells
6:47 Why Immune Health is Key to Longevity
10:05 Future Trials: Cancer and Vaccination Response
🌐Links in this video
Time-Line home page https://www.timeline.com/
ATLAS Trial: Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults
https://pubmed.ncbi.nlm.nih.gov/35584623/
Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial
https://www.nature.com/articles/s43587-025-00996-x
#ImmuneAging
#CD8TCells
#Immunometabolism
Modern Healthspan · 12 min · Source published: 2026-03-29
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.